Header Logo

Connection

VINCENT TAM to Microbial Sensitivity Tests

Back to Details
This is a "connection" page, showing publications VINCENT TAM has written about Microbial Sensitivity Tests.
VINCENT TAM
Connection Strength
7.305
Microbial Sensitivity Tests
  1. In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 Sep; 38:252-255.
    View in: PubMed
    Score: 0.700
  2. Alternative iron-depleted media for cefiderocol susceptibility testing. Int J Antimicrob Agents. 2024 Jul; 64(1):107193.
    View in: PubMed
    Score: 0.692
  3. Comparison of cefiderocol in-vitro susceptibility testing modalities. J Glob Antimicrob Resist. 2024 06; 37:100-101.
    View in: PubMed
    Score: 0.686
  4. A novel framework to compare the effectiveness of ?-lactamase inhibitors against extended-spectrum ?-lactamase-producing Enterobacteriaceae. Clin Microbiol Infect. 2019 Sep; 25(9):1154.e9-1154.e14.
    View in: PubMed
    Score: 0.479
  5. Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii. Diagn Microbiol Infect Dis. 2025 Nov; 113(3):116991.
    View in: PubMed
    Score: 0.187
  6. Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible Staphylococcus aureus in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection. Antimicrob Agents Chemother. 2024 11 06; 68(11):e0089824.
    View in: PubMed
    Score: 0.178
  7. Growth of Acinetobacter baumannii impacted by iron chelation. Lett Appl Microbiol. 2023 Feb 16; 76(2).
    View in: PubMed
    Score: 0.159
  8. Clinical and genomic analysis of virulence-related genes in bloodstream infections caused by Acinetobacter baumannii. Virulence. 2022 Dec; 13(1):1920-1927.
    View in: PubMed
    Score: 0.157
  9. Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137.
    View in: PubMed
    Score: 0.156
  10. An integrated approach to evaluate different tetracycline derivatives for formulary decisions. Am J Health Syst Pharm. 2022 03 07; 79(6):467-471.
    View in: PubMed
    Score: 0.149
  11. Clinical outcomes of cystic fibrosis patients with Pseudomonas aeruginosa bloodstream infection. J Glob Antimicrob Resist. 2022 06; 29:551-552.
    View in: PubMed
    Score: 0.146
  12. Hydrolytic activity of KPC-producing Klebsiella pneumoniae clinical isolates. J Chemother. 2022 09; 34(5):345-346.
    View in: PubMed
    Score: 0.146
  13. Optimizing pharmacokinetics/pharmacodynamics of ?-lactam/?-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria. J Antimicrob Chemother. 2021 01 01; 76(1):179-183.
    View in: PubMed
    Score: 0.137
  14. MIC profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates. J Glob Antimicrob Resist. 2020 12; 23:385-387.
    View in: PubMed
    Score: 0.136
  15. The impact of serum protein binding on bacterial killing of minocycline. J Glob Antimicrob Resist. 2020 06; 21:252-254.
    View in: PubMed
    Score: 0.127
  16. Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist. 2017 12; 11:154-155.
    View in: PubMed
    Score: 0.110
  17. The complexity of minocycline serum protein binding. J Antimicrob Chemother. 2017 06 01; 72(6):1632-1634.
    View in: PubMed
    Score: 0.107
  18. Determining ?-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother. 2017 05 01; 72(5):1421-1428.
    View in: PubMed
    Score: 0.106
  19. Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. Antimicrob Agents Chemother. 2017 05; 61(5).
    View in: PubMed
    Score: 0.106
  20. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 May; 59(5):2720-5.
    View in: PubMed
    Score: 0.091
  21. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015 May; 45(5):541-4.
    View in: PubMed
    Score: 0.091
  22. In vitro ceftriaxone susceptibility in methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2015 Feb; 59(2):1370.
    View in: PubMed
    Score: 0.090
  23. Correlation of hospital carbapenem consumption and resistance trends in selected gram-negative bacteria. Ann Pharmacother. 2012 Jul-Aug; 46(7-8):1120-2.
    View in: PubMed
    Score: 0.076
  24. In vitro activity of MK-7655, a novel ?-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012 Jul; 56(7):3753-7.
    View in: PubMed
    Score: 0.075
  25. Novel modeling framework to guide design of optimal dosing strategies for ?-lactamase inhibitors. Antimicrob Agents Chemother. 2012 May; 56(5):2237-40.
    View in: PubMed
    Score: 0.074
  26. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother. 2012 Apr; 56(4):1680-5.
    View in: PubMed
    Score: 0.074
  27. Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia model. Antimicrob Agents Chemother. 2011 Oct; 55(10):4601-5.
    View in: PubMed
    Score: 0.071
  28. In vitro potency of various polymyxin B components. Antimicrob Agents Chemother. 2011 Sep; 55(9):4490-1.
    View in: PubMed
    Score: 0.071
  29. Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. J Antimicrob Chemother. 2011 May; 66(5):1079-86.
    View in: PubMed
    Score: 0.069
  30. Emergence of KPC-producing Klebsiella pneumoniae in Texas. Diagn Microbiol Infect Dis. 2011 Feb; 69(2):234-5.
    View in: PubMed
    Score: 0.069
  31. A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. PLoS Comput Biol. 2011 Jan 06; 7(1):e1001043.
    View in: PubMed
    Score: 0.069
  32. Mathematical modeling to characterize the inoculum effect. Antimicrob Agents Chemother. 2010 Nov; 54(11):4739-43.
    View in: PubMed
    Score: 0.067
  33. Impact of recA on levofloxacin exposure-related resistance development. Antimicrob Agents Chemother. 2010 Oct; 54(10):4262-8.
    View in: PubMed
    Score: 0.067
  34. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010 Jun; 65(6):1119-25.
    View in: PubMed
    Score: 0.065
  35. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Mar; 54(3):1160-4.
    View in: PubMed
    Score: 0.064
  36. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20.
    View in: PubMed
    Score: 0.059
  37. Killing activity of rifampin with piperacillin therapy against adherent cells of Pseumodomas aeruginosa. J Chemother. 2008 Oct; 20(5):652-4.
    View in: PubMed
    Score: 0.059
  38. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother. 2008 Nov; 52(11):3987-93.
    View in: PubMed
    Score: 0.058
  39. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2008 Aug; 52(8):2898-904.
    View in: PubMed
    Score: 0.057
  40. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7.
    View in: PubMed
    Score: 0.056
  41. Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother. 2007 Dec; 60(6):1302-9.
    View in: PubMed
    Score: 0.055
  42. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):309-14.
    View in: PubMed
    Score: 0.054
  43. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis. 2007 Jun 15; 195(12):1818-27.
    View in: PubMed
    Score: 0.053
  44. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother. 2007 Feb; 51(2):744-7.
    View in: PubMed
    Score: 0.052
  45. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006 Aug; 50(8):2626-31.
    View in: PubMed
    Score: 0.050
  46. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Dec; 49(12):4920-7.
    View in: PubMed
    Score: 0.048
  47. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Sep; 49(9):3624-30.
    View in: PubMed
    Score: 0.047
  48. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis. 2005 Aug 01; 192(3):420-8.
    View in: PubMed
    Score: 0.047
  49. Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2005 Jun; 52(2):145-51.
    View in: PubMed
    Score: 0.047
  50. Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother. 2005 May; 55(5):699-706.
    View in: PubMed
    Score: 0.046
  51. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob Agents Chemother. 2004 Nov; 48(11):4315-21.
    View in: PubMed
    Score: 0.045
  52. The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy. Antimicrob Agents Chemother. 2024 01 10; 68(1):e0100923.
    View in: PubMed
    Score: 0.042
  53. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother. 2003 Jun; 47(6):1853-61.
    View in: PubMed
    Score: 0.041
  54. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy. 2003 Mar; 23(3):291-5.
    View in: PubMed
    Score: 0.040
  55. A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760.
    View in: PubMed
    Score: 0.040
  56. Deciphering longitudinal optical-density measurements to guide clinical dosing regimen design: A model-based approach. Comput Methods Programs Biomed. 2022 Dec; 227:107212.
    View in: PubMed
    Score: 0.039
  57. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002 Sep; 50(3):425-8.
    View in: PubMed
    Score: 0.038
  58. In vitro activity of tigecycline and proteomic analysis of tigecycline adaptation strategies in clinical Enterococcus faecalis isolates from China. J Glob Antimicrob Resist. 2022 09; 30:66-74.
    View in: PubMed
    Score: 0.038
  59. New ?-Lactam-?-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020 12 16; 34(1).
    View in: PubMed
    Score: 0.034
  60. Prolonged Versus Intermittent Infusion of ?-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. Clin Pharmacokinet. 2020 10; 59(10):1237-1250.
    View in: PubMed
    Score: 0.034
  61. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-?-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2019 02; 63(2).
    View in: PubMed
    Score: 0.030
  62. Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital. J Chemother. 2018 Apr; 30(2):115-119.
    View in: PubMed
    Score: 0.028
  63. The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques. Antimicrob Agents Chemother. 2017 08; 61(8).
    View in: PubMed
    Score: 0.027
  64. Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis. Antimicrob Agents Chemother. 2017 07; 61(7).
    View in: PubMed
    Score: 0.027
  65. Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis. Antimicrob Agents Chemother. 2017 06; 61(6).
    View in: PubMed
    Score: 0.027
  66. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015 Feb; 15(2):225-34.
    View in: PubMed
    Score: 0.022
  67. An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. J Infect Chemother. 2014 Mar; 20(3):224-7.
    View in: PubMed
    Score: 0.021
  68. Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother. 2010 Mar; 54(3):1173-8.
    View in: PubMed
    Score: 0.016
  69. Polymyxins: a review of the current status including recent developments. Ann Acad Med Singap. 2008 Oct; 37(10):870-83.
    View in: PubMed
    Score: 0.015
  70. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007 Oct; 5(5):811-21.
    View in: PubMed
    Score: 0.014
  71. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006 Feb; 50(2):469-73.
    View in: PubMed
    Score: 0.012
  72. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis. 2006 Mar; 54(3):223-30.
    View in: PubMed
    Score: 0.012
  73. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006 Jan; 50(1):310-7.
    View in: PubMed
    Score: 0.012
  74. Disposition of cefepime in the central nervous system of patients with external ventricular drains. Pharmacotherapy. 2003 Mar; 23(3):310-4.
    View in: PubMed
    Score: 0.010
  75. Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and review. Pharmacotherapy. 2001 Aug; 21(8):998-1002.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.